PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28099407-2 2017 We investigated whether the variant genotypes of cytochrome P450 2C8 (CYP2C8), CYP2C9, CYP3A5 and transporter ABCB1 influence the pharmacokinetic phenotype of the substrate pioglitazone in Chinese individuals. Pioglitazone 173-185 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 49-68 29663414-1 2018 Amodiaquine (AQ) and pioglitazone (PGZ) are both metabolized by CYP2C8, an enzyme also inhibited by PGZ. Pioglitazone 21-33 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 64-70 29663414-1 2018 Amodiaquine (AQ) and pioglitazone (PGZ) are both metabolized by CYP2C8, an enzyme also inhibited by PGZ. Pioglitazone 35-38 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 64-70 29663414-1 2018 Amodiaquine (AQ) and pioglitazone (PGZ) are both metabolized by CYP2C8, an enzyme also inhibited by PGZ. Pioglitazone 100-103 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 64-70 29545948-1 2018 This study was conducted to evaluate the likelihood of daprodustat to act as a perpetrator in drug-drug interactions (DDI) with the CYP2C8 enzyme and OATP1B1 transporter using the probe substrates pioglitazone and rosuvastatin as potential victims, respectively. Pioglitazone 197-209 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 132-138 29174535-4 2017 Inter-individual variability in the hepatic intrinsic clearance of CYP2C8 substrates (CLint,h,2C8) was estimated from the inter-individual variability in pharmacokinetics of pioglitazone, which is a major CYP2C8 substrate. Pioglitazone 174-186 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 67-73 29174535-4 2017 Inter-individual variability in the hepatic intrinsic clearance of CYP2C8 substrates (CLint,h,2C8) was estimated from the inter-individual variability in pharmacokinetics of pioglitazone, which is a major CYP2C8 substrate. Pioglitazone 174-186 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 205-211 28340451-5 2017 Since enzalutamide is extensively metabolized by CYP2C8, its plasma levels are likely to be raised if coadministered with strong CYP2C8 inhibitors such as gemfibrozil or pioglitazone. Pioglitazone 170-182 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 49-55 28340451-5 2017 Since enzalutamide is extensively metabolized by CYP2C8, its plasma levels are likely to be raised if coadministered with strong CYP2C8 inhibitors such as gemfibrozil or pioglitazone. Pioglitazone 170-182 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 129-135 27599706-4 2017 METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs. Pioglitazone 181-193 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 136-142 31129789-5 2019 METHODS: PBPK models of the CYP2C8 and organic-anion-transporting polypeptide (OATP) 1B1 perpetrator drug gemfibrozil (parent-metabolite model) and the CYP2C8 victim drugs repaglinide (also an OATP1B1 substrate) and pioglitazone were developed using a total of 103 clinical studies. Pioglitazone 216-228 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 28-34 31204932-6 2019 CONCLUSIONS: Pioglitazone can reverse the adriamycin-resistance in K562/ADR cells that is closely related to the decrease of protein expression of CYP2C8 and CYP2J2. Pioglitazone 13-25 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 147-153 28099407-2 2017 We investigated whether the variant genotypes of cytochrome P450 2C8 (CYP2C8), CYP2C9, CYP3A5 and transporter ABCB1 influence the pharmacokinetic phenotype of the substrate pioglitazone in Chinese individuals. Pioglitazone 173-185 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 70-76 27504016-5 2016 To explore the clinical relevance of the in vitro data, an open-label, single-center study was conducted comprising 16 healthy male subjects who received a single 15-mg dose of the CYP2C8 substrate pioglitazone on day 1 and again 1 hour after the administration of abiraterone acetate 1000 mg on day 8. Pioglitazone 198-210 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 181-187 27457785-5 2016 In addition, the AUC of pioglitazone M4, a CYP2C8-mediated metabolite of pioglitazone, was reduced to 70% of the control by coadministration of clopidogrel. Pioglitazone 24-36 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 43-49 27457785-5 2016 In addition, the AUC of pioglitazone M4, a CYP2C8-mediated metabolite of pioglitazone, was reduced to 70% of the control by coadministration of clopidogrel. Pioglitazone 73-85 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 43-49 24324437-6 2013 The genes CYP2C8 and PPARG are the most extensively studied to date and selected polymorphisms contribute to respective variability in pioglitazone pharmacokinetics and pharmacodynamics. Pioglitazone 135-147 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 10-16 27260150-0 2016 Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. Pioglitazone 73-85 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 56-62 27260150-1 2016 The glucose-lowering drug pioglitazone undergoes hepatic CYP2C8-mediated biotransformation to its main metabolites. Pioglitazone 26-38 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 57-63 27260150-10 2016 Clopidogrel increases the exposure to pioglitazone by inhibiting its CYP2C8-mediated biotransformation. Pioglitazone 38-50 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 69-75 27163495-0 2016 Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies. Pioglitazone 72-84 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 55-61 27163495-5 2016 The effect of fostamatinib (100 mg twice daily) on the pharmacokinetics of a single oral 30-mg dose of the CYP2C8 substrate pioglitazone and its metabolite, hydroxy pioglitazone, was then investigated (open-label, nonrandomized, 2-period phase I study [n = 15]). Pioglitazone 124-136 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 107-113 26296069-1 2015 PURPOSE: Repaglinide and pioglitazone are both CYP2C8 and CYP3A4 substrates. Pioglitazone 25-37 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 47-53 23712614-0 2013 Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pioglitazone 49-61 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 13-19 23712614-9 2013 However, the M-III:pioglitazone AUC0-48 ratio was significantly lower in CYP2C8*2 carriers than CYP2C8*1 homozygotes (0.70 +- 0.15 vs 1.2 +- 0.37, p=0.006). Pioglitazone 19-31 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 73-79 23712614-11 2013 CONCLUSION: These data suggest that CYP2C8*2 influences pioglitazone pharmacokinetics in vivo, particularly the AUC0-48 ratio of M-III:parent drug, and the AUC0-48 ratio of M-III:M-IV. Pioglitazone 56-68 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 36-42 19614891-0 2009 The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Pioglitazone 48-60 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 18-24 23370354-12 2013 In summary, CYP2C8*3 significantly affected pioglitazone CL/F, Q/F, and interindividual variability in these parameters in this healthy volunteer cohort. Pioglitazone 44-56 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 12-18 20875371-2 2010 This study aimed to investigate any potential pharmacokinetic interaction between linagliptin and pioglitazone, a CYP 2C8 substrate. Pioglitazone 98-110 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 114-121 19614891-6 2009 Mean intrinsic clearance of pioglitazone to the metabolite M-IV was highest for CYP2C8 and CYP1A2 with 58 pmol M-IV/min/nmol CYP P450/microM pioglitazone each, 53 for CYP2D6*1, 40 for CYP2C19*1, and 34 for CYP2C9*2, respectively. Pioglitazone 141-153 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 80-86 19614891-8 2009 CYP2C8*1/*1 microsomes (25 +/- 4 pmol M-IV/min/mg protein/muM pioglitazone) showed lower intrinsic clearance of pioglitazone than CYP2C8*3/*3 microsomes (35 +/- 9, p = 0.04). Pioglitazone 62-74 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 0-6 19614891-8 2009 CYP2C8*1/*1 microsomes (25 +/- 4 pmol M-IV/min/mg protein/muM pioglitazone) showed lower intrinsic clearance of pioglitazone than CYP2C8*3/*3 microsomes (35 +/- 9, p = 0.04). Pioglitazone 112-124 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 0-6 23370354-0 2013 Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Pioglitazone 70-82 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 10-29 23370354-2 2013 Pioglitazone undergoes hepatic metabolism by cytochrome P450 2C8 (CYP2C8) and interindividual variability exists in pioglitazone disposition and response. Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 45-64 23370354-2 2013 Pioglitazone undergoes hepatic metabolism by cytochrome P450 2C8 (CYP2C8) and interindividual variability exists in pioglitazone disposition and response. Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 66-72 23370354-3 2013 In previous analyses, it has been shown that the CYP2C8*3 polymorphism significantly impacts pioglitazone pharmacokinetics in humans. Pioglitazone 93-105 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 49-55 23370354-4 2013 The purpose of this investigation was to develop a population pharmacokinetic model using nonlinear mixed effects analysis to evaluate and quantify the effect of CYP2C8*3, demographic, and clinical variables on interindividual variability in pioglitazone pharmacokinetics in nondiabetic adults. Pioglitazone 242-254 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 162-168 23370354-8 2013 Covariate analysis revealed that CYP2C8*3 had a significant effect on pioglitazone central compartment clearance (CL/F; p=0.0005) and intercompartmental clearance (Q/F; p=0.004). Pioglitazone 70-82 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 33-39 22625877-0 2013 Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Pioglitazone 90-102 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 14-20 22625877-1 2013 AIM: The objective of this study was to determine the extent to which the CYP2C8*3 allele influences pharmacokinetic variability in the drug-drug interaction between gemfibrozil (CYP2C8 inhibitor) and pioglitazone (CYP2C8 substrate). Pioglitazone 201-213 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 74-80 22625877-6 2013 When pioglitazone was administered alone, the mean AUC(0, ) was 29.7% lower (P = 0.01) in CYP2C8*3 carriers compared with CYP2C8*1 homozygotes. Pioglitazone 5-17 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 90-96 22625877-6 2013 When pioglitazone was administered alone, the mean AUC(0, ) was 29.7% lower (P = 0.01) in CYP2C8*3 carriers compared with CYP2C8*1 homozygotes. Pioglitazone 5-17 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 122-128 22625877-7 2013 The relative change in pioglitazone plasma exposure following gemfibrozil administration was significantly influenced by CYP2C8 genotype. Pioglitazone 23-35 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 121-127 22625877-8 2013 Specifically, CYP2C8*3 carriers had a 5.2-fold mean increase in pioglitazone AUC(0, ) compared with a 3.3-fold mean increase in CYP2C8*1 homozygotes (P = 0.02). Pioglitazone 64-76 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 14-20 22625877-9 2013 CONCLUSION: CYP2C8*3 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction. Pioglitazone 50-62 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 12-18 22625877-9 2013 CONCLUSION: CYP2C8*3 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction. Pioglitazone 165-177 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 12-18 19614891-1 2009 The cytochrome P450 enzyme CYP2C8 appears to have a major role in pioglitazone metabolism. Pioglitazone 66-78 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 27-33 19614891-2 2009 The present study was conducted to further clarify the role of individual CYPs and of the CYP2C8/9 polymorphisms in the primary metabolism of pioglitazone in vitro. Pioglitazone 142-154 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 90-96 19614891-3 2009 Pioglitazone (2-400 microM) was incubated with isolated cytochrome P450 enzymes or human liver microsomes, some of them carrying either the CYP2C8*3/*3 genotype (and also the CYP2C9*2/*2 genotype) or the CYP2C8*1/*1 genotype (five samples each). Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 140-146 19614891-3 2009 Pioglitazone (2-400 microM) was incubated with isolated cytochrome P450 enzymes or human liver microsomes, some of them carrying either the CYP2C8*3/*3 genotype (and also the CYP2C9*2/*2 genotype) or the CYP2C8*1/*1 genotype (five samples each). Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 204-210 19614891-6 2009 Mean intrinsic clearance of pioglitazone to the metabolite M-IV was highest for CYP2C8 and CYP1A2 with 58 pmol M-IV/min/nmol CYP P450/microM pioglitazone each, 53 for CYP2D6*1, 40 for CYP2C19*1, and 34 for CYP2C9*2, respectively. Pioglitazone 28-40 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 80-86 19761371-5 2009 Contrary to in vitro data, clinical data suggest that the CYP2C8*3 allele is associated with increased metabolism of the CYP2C8 substrates, rosiglitazone, pioglitazone and repaglinide. Pioglitazone 155-167 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 58-64 19761371-5 2009 Contrary to in vitro data, clinical data suggest that the CYP2C8*3 allele is associated with increased metabolism of the CYP2C8 substrates, rosiglitazone, pioglitazone and repaglinide. Pioglitazone 155-167 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 121-127 17913794-0 2008 Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Pioglitazone 86-98 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 21-27 17901929-4 2008 The impact of CYP2C8 time-dependent inhibition by gemfibrozil acyl-glucuronide was assessed using repaglinide, cerivastatin, loperamide, rosiglitazone and pioglitazone DDIs. Pioglitazone 155-167 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 14-20 17913794-1 2008 We studied the effects of the CYP2C8 inhibitor trimethoprim and CYP2C8 genotype on the pharmacokinetics of the antidiabetic pioglitazone. Pioglitazone 124-136 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 30-36 17913794-1 2008 We studied the effects of the CYP2C8 inhibitor trimethoprim and CYP2C8 genotype on the pharmacokinetics of the antidiabetic pioglitazone. Pioglitazone 124-136 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 64-70 17913794-6 2008 During the placebo phase, the weight-adjusted AUC(0-infinity) of pioglitazone was 34% smaller in the CYP2C8(*)3/(*)3 group and 26% smaller in the CYP2C8(*)1/(*)3 group than in the CYP2C8(*)1/(*)1 group (p < 0.05). Pioglitazone 65-77 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 101-107 17913794-6 2008 During the placebo phase, the weight-adjusted AUC(0-infinity) of pioglitazone was 34% smaller in the CYP2C8(*)3/(*)3 group and 26% smaller in the CYP2C8(*)1/(*)3 group than in the CYP2C8(*)1/(*)1 group (p < 0.05). Pioglitazone 65-77 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 146-152 17913794-6 2008 During the placebo phase, the weight-adjusted AUC(0-infinity) of pioglitazone was 34% smaller in the CYP2C8(*)3/(*)3 group and 26% smaller in the CYP2C8(*)1/(*)3 group than in the CYP2C8(*)1/(*)1 group (p < 0.05). Pioglitazone 65-77 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 146-152 17913794-8 2008 In conclusion, drug interactions and pharmacogenetics affecting the CYP2C8 enzyme may change the safety of pioglitazone. Pioglitazone 107-119 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 68-74 17214065-1 2006 BACKGROUND: Pioglitazone is a thiazolidinedione compound used in the treatment of type 2 diabetes, metabolized mainly by CYP2C8 and CYP3A4. Pioglitazone 12-24 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 121-127 17201456-6 2007 CYP2C8 and CYP3A4 are the main isoenzymes catalysing biotransformation of pioglitazone (as with troglitazone), whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8. Pioglitazone 74-86 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 0-6 16867170-3 2006 The metabolism of pioglitazone by CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 was investigated using human recombinant CYP isoforms. Pioglitazone 18-30 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 50-56 16867170-0 2006 Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 31-37 16867170-0 2006 Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 91-97 16867170-4 2006 In particular, the inhibitors of CYP2C8, but also those of CYP3A4, markedly inhibited the elimination of pioglitazone and the formation of M-IV by HLM. Pioglitazone 105-117 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 33-39 16867170-6 2006 Of the recombinant isoforms, CYP2C8 (20 pmol/ml) metabolised pioglitazone markedly (56% in 60 min. Pioglitazone 61-73 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 29-35 16867170-9 2006 In conclusion, pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro. Pioglitazone 15-27 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 53-59 16867170-11 2006 The effect of different CYP2C8 inhibitors on pioglitazone pharmacokinetics needs to be evaluated also in vivo because, irrespective of their in vitro CYP2C8 inhibitory potency, their pharmacokinetic properties may affect the extent of interaction. Pioglitazone 45-57 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 24-30 16670899-1 2006 OBJECTIVE: Pioglitazone, a thiazolidinedione antidiabetic drug, is metabolised mainly by the cytochrome P450 (CYP) 2C8 enzyme. Pioglitazone 11-23 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 93-118 16447051-0 2006 Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Pioglitazone 0-12 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 39-45 16447051-10 2006 CONCLUSIONS: Pioglitazone does not increase the plasma concentrations of repaglinide, indicating that the inhibitory effect of pioglitazone on CYP2C8 and CYP3A4 is very weak in vivo, probably due to its extensive plasma protein binding. Pioglitazone 127-139 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 143-149 16447051-1 2006 OBJECTIVE: Pioglitazone, a thiazolidinedione antidiabetic, inhibits cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes in vitro. Pioglitazone 11-23 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 68-93 16299161-9 2006 The results described have important implications for the mechanism of the clinical interaction reported between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone. Pioglitazone 201-213 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 129-135 16390353-1 2006 AIMS: The effect of enzyme induction on the pharmacokinetics of pioglitazone, a thiazolidinedione antidiabetic drug that is metabolized primarily by CYP2C8, is not known. Pioglitazone 64-76 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 149-155 16390353-11 2006 CONCLUSIONS: Rifampicin caused a substantial decrease in the plasma concentration of pioglitazone, probably by induction of CYP2C8. Pioglitazone 85-97 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 124-130 11921435-7 2002 Further differences in the safety profiles of these agents arise because the oxidative metabolism for each agent occurs by distinct cytochrome pathways: troglitazone and pioglitazone involve CYP 3A4 and CYP 2C8 whereas rosiglitazone is principally metabolized by CYP 2C8. Pioglitazone 170-182 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 203-210 15900286-1 2005 BACKGROUND AND OBJECTIVE: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P450 (CYP) 2C8 and CYP3A4 in vitro. Pioglitazone 66-78 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 104-129 15900286-11 2005 CONCLUSIONS: Gemfibrozil elevates the plasma concentrations of pioglitazone, probably by inhibition of its CYP2C8-mediated metabolism. Pioglitazone 63-75 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 107-113 15900286-12 2005 CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metabolism in vivo in humans. Pioglitazone 75-87 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 0-6 16372821-14 2005 CYP2C8 and CYP3A4 are the main enzymes catalysing biotransformation of the thiazolidinediones troglitazone and pioglitazone, whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8. Pioglitazone 111-123 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 0-6 16372821-14 2005 CYP2C8 and CYP3A4 are the main enzymes catalysing biotransformation of the thiazolidinediones troglitazone and pioglitazone, whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8. Pioglitazone 111-123 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 176-182 16283275-1 2005 OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4. Pioglitazone 92-104 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 163-169 11921435-7 2002 Further differences in the safety profiles of these agents arise because the oxidative metabolism for each agent occurs by distinct cytochrome pathways: troglitazone and pioglitazone involve CYP 3A4 and CYP 2C8 whereas rosiglitazone is principally metabolized by CYP 2C8. Pioglitazone 170-182 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 263-270